Skip to content

kpv

KPV peptide research: what it has been studied for, in plain English

Research overview 7 min read

On this page
  1. What is KPV?
  2. What is KPV peptide used for?
  3. KPV research areas at a glance
  4. How is KPV thought to work?
  5. What kind of studies are these?
  6. Sources

KPV is a peptide made of three amino acids, the last three of the hormone alpha-MSH [G1]. In research, it has mainly been studied for how it affects inflammation signals in lab-grown cells and in mouse models of colitis [G2, G3]. Smaller lines of work looked at skin cells and at wounds on the surface of the eye in rabbits [G9, G10]. The studies in this overview are cell and animal work [G2–G10].

What is KPV?

A peptide is a short chain of amino acids, the building blocks of proteins. KPV has three of them: lysine, proline and valine, written Lys-Pro-Val or KPV [G2].

Those three are the end of a longer peptide. Alpha-melanocyte-stimulating hormone (alpha-MSH) is a hormone made of 13 amino acids, cut from a larger precursor protein called proopiomelanocortin [G1]. KPV is its last three amino acids, positions 11 to 13, which is why papers also call it alpha-MSH(11-13) [G1, G3].

What is KPV peptide used for?

In research, KPV has mainly been studied for how it changes inflammation signals in cells and in mice [G2, G3]. The research areas, in plain terms:

  • Inflammation signals in human cells grown in the lab. Researchers added KPV to gut-lining cells, immune T cells and airway cells exposed to inflammatory triggers, and measured inflammation switches and the release of cytokines, the chemical messengers of inflammation [G2, G7].
  • Mouse models of colitis. Colitis is inflammation of the large bowel. In mice, it was brought on by chemicals or by transferring certain immune cells [G2, G3]. Researchers then examined colon tissue and inflammation markers in mice given KPV [G2, G3].
  • Carrying KPV to the colon. Two studies packed KPV into nanoparticles, tiny polymer particles, held inside a gel designed to release them in the colon, and tested this in gut cells and in mice with colitis [G4, G5].
  • Inflammatory cells gathering in the abdomen. One mouse study counted neutrophils, a type of white blood cell, that collected in the abdominal lining after an inflammatory trigger [G6].
  • Skin cells and the eye surface. One study exposed keratinocytes, the main cells of the skin's outer layer, to fine airborne dust particles [G9]. Another measured how much of a scraped area on the rabbit cornea, the clear front surface of the eye, remained over time [G10].

In Kannengiesser et al.'s colitis models, colon tissue showed fewer inflammatory cells in mice given KPV, and in the DSS model MPO, an enzyme that marks neutrophil build-up, measured lower [G3]. Dalmasso et al. reported less colitis in mice given KPV, judged by colon tissue and by lower inflammatory-cytokine levels [G2]. With the nanoparticle gel, inflammatory and tissue measures in mice with colitis were lower than in mice given the colitis trigger alone [G4]. Xiao et al. compared nanoparticles coated with hyaluronic acid against uncoated KPV nanoparticles in a mouse colitis model, and reported less damage to the mucosa (the colon's inner lining) and lower TNF-α, an inflammatory messenger, with the coated version [G5]. In the mouse peritonitis models, fewer neutrophils gathered in the abdominal lining with KPV [G6].

KPV research areas at a glance

Area What researchers looked at Models How strong the evidence is
Inflammation signals in cells NF-κB activity (a switch for inflammation genes) and the release of inflammatory messengers [G2, G7] Human gut-lining, T-cell and airway cell lines [G2, G7] Lab cell studies [G2, G7]
Gut inflammation (colitis) Colon tissue under the microscope, inflammatory messengers, and MPO, an enzyme marker of neutrophil build-up [G2, G3] Mouse DSS, TNBS and T-cell transfer colitis [G2, G3] Animal studies (mice) [G2, G3]
Delivery to the colon KPV carried in nanoparticles inside a gel; inflammatory and tissue measures [G4, G5] Gut cells in culture; mouse colitis [G4, G5] Cell and animal studies [G4, G5]
Inflammatory-cell build-up Numbers of neutrophils gathering in the abdominal lining [G6] Mouse peritonitis (inflamed abdominal lining) [G6] One animal study [G6]
Skin cells and eye-surface wounds Cell survival, oxidative stress and inflammatory messengers in skin cells; size of a scraped area on the cornea over time [G9, G10] Human skin cell line and 3D skin model; rabbit cornea [G9, G10] One cell study and one animal study [G9, G10]
Studies in people What was checked: the ClinicalTrials.gov registry, for "KPV", "Lys-Pro-Val" and "alpha-MSH 11-13" [G11] None listed in an October 2026 registry search [G11] No human evidence to assess [G11]

Evidence levels describe the study types in the sources listed; they are not a grading by the sources' authors.

How is KPV thought to work?

Every finding below comes from cells, tissue or animals.

Getting into cells: PepT1. PepT1 is a transporter, a protein doorway in the cell membrane, that carries pieces two or three amino acids long into cells. Dalmasso et al. noted it is normally found in the small intestine and is induced in the colon during inflammatory bowel disease (IBD) [G2]. Their uptake experiments indicated that KPV enters gut-lining and immune cells through PepT1 [G2].

The NF-κB switch. NF-κB is a protein complex that turns on inflammation genes once it moves into the cell's nucleus. In gut and T cells, Dalmasso et al. observed that KPV inhibited NF-κB and MAP kinase signalling (another inflammation relay) and reduced cytokine release [G2]. Land studied human airway cells triggered with TNF-α or a respiratory virus (RSV) and observed concentration-dependent inhibition of NF-κB activity and of IL-8 and eotaxin release, two messengers that call in immune cells [G7]. In those cells KPV entered the nucleus, IκBα (the brake that holds NF-κB outside the nucleus) was stabilised, and the p65 part of NF-κB moved into the nucleus less [G7]. Competition assays pointed to the site where p65 binds importin-α3, a carrier that ferries proteins into the nucleus [G7].

The receptor question. Alpha-MSH acts through melanocortin receptors, proteins on the cell surface that pick up the hormone [G1]. For KPV the sources differ. Getting et al. still saw fewer neutrophils gather with KPV in mice whose MC1R receptor did not work, and when an MC3/4 receptor blocker was given [G6]. In cultured immune cells, KPV did not raise cAMP, a signalling molecule the melanocortin receptors use [G6]. They concluded KPV "is unlikely to mediate its effects through melanocortin receptors but is more likely to act through inhibition of IL-1beta functions" [G6]. Kannengiesser et al. concluded the colitis effects "seem to be at least partially independent of MC1R signaling" [G3]. Elliott et al. saw no cAMP rise in skin cells [G8]. They recorded a rapid calcium signal in normal keratinocytes, and in a keratinocyte cell line only when a compound that dampens the cAMP pathway was added [G8]. KPV peptides also raised calcium in cells engineered to carry MC1R [G8].

Oxidative stress and nitric oxide. In skin cells exposed to dust particles, Sung et al. reported lower reactive oxygen species (ROS, unstable oxygen molecules that damage cells), lower IL-1β and less inflammatory cell death with KPV, along with lower ERK, p38 and caspase-1 activity [G9]. In the rabbit cornea, the remaining wound area, measured every 12 hours, was smaller with KPV than with a saline control [G10]. Giving L-NAME, a blocker of nitric oxide production, beforehand weakened that effect, so the authors proposed a role for nitric oxide, a short-lived signalling gas [G10].

What kind of studies are these?

Studies come in three broad kinds. Cell studies test a compound on cells in a dish. Animal studies test it in a whole living animal, not a person. Together, cell and animal work is called preclinical research. Only human studies show what happens in people.

Every KPV study cited here was preclinical: it used cells, tissue models, mice or rabbits [G2–G10]. A search of the ClinicalTrials.gov registry in October 2026 listed no registered study of KPV [G11].

Several of the colitis and delivery studies came from one research group [G2, G4, G5].

For the same kind of map of another research peptide, see how the BPC-157 research is laid out.

Back to the Limitless Science home page.

Sources

All products are sold for laboratory research use only. Not for human or veterinary use. Nothing on this page is medical advice.

Keep reading